Primary Research · 2003
Effects of Boswellia serrata gum resin in patients with osteoarthritis of knee
Kimmatkar N, Thawani V, Hingorani L, Khiyani R · Phytomedicine, 2003
Key finding
8-week crossover RCT (n=30) found Boswellia serrata extract significantly reduced knee pain, increased flexion, and improved walking distance in osteoarthritis vs placebo.
Abstract
PubMed · PMID 12622457 →Osteoarthritis is a common, chronic, progressive, skeletal, degenerative disorder, which commonly affects the knee joint. Boswellia serrata tree is commonly found in India. The therapeutic value of its gum (guggulu) has been known. It posses good anti-inflammatory, anti-arthritic and analgesic activity. A randomized double blind placebo controlled crossover study was conducted to assess the efficacy, safety and tolerability of Boswellia serrata Extract (BSE) in 30 patients of osteoarthritis of knee, 15 each receiving active drug or placebo for eight weeks. After the first intervention, washout was given and then the groups were crossed over to receive the opposite intervention for eight weeks. All patients receiving drug treatment reported decrease in knee pain, increased knee flexion and increased walking distance. The frequency of swelling in the knee joint was decreased. Radiologically there was no change. The observed differences between drug treated and placebo being statistically significant, are clinically relevant. BSE was well tolerated by the subjects except for minor gastrointestinal ADRs. BSE is recommended in the patients of osteoarthritis of the knee with possible therapeutic use in other arthritis.
Abstract sourced from PubMed, a database of the U.S. National Library of Medicine. Displayed in the authors’ own words for context; our critique is in the sections below.
D
48/100
Preliminary evidence
Major design weaknesses. This is a hypothesis-generating result that needs a better-designed follow-up before it should influence decisions.
Strengths
No notable design strengths identified.
Limitations
- ⚠Small sample size
- ⚠Short duration
- ⚠Single-center
- ⚠No active comparator
- ⚠Unreplicated
Critique
Widely cited as evidence that boswellia works for knee osteoarthritis, but the trial has substantial methodological limitations. n=30 in a crossover design means each condition was observed in effectively 15 patients at a time, which is underpowered for the reported effect magnitude. 8 weeks total is short for osteoarthritis symptom trajectories. Outcomes were subjective, there was no active comparator, and the study was single-center. Later boswellia trials have used different extract forms (5-LOXIN, Aflapin) at different doses, so there is no direct replication of the specific intervention tested here.
What would be more convincing
An 800-patient multi-center RCT comparing a standardized boswellia serrata extract at a fixed dose against an active comparator (e.g., celecoxib or ibuprofen) with 12-week duration and WOMAC as the primary outcome would move boswellia from 'plausibly useful for OA' to 'evidence-supported.'
Reviewed 2026-04-21 · Opinion based on verifiable facts in the published paper.
What these flags mean for you
Each flag on this study comes with a plain-English breakdown of why it matters and how it should change the confidence you place in the result.
Small sample size
What it means
The study enrolled too few participants for its results to be statistically reliable on their own.
Why it matters
With a small sample, random variation can look like a real effect. A positive finding in 20 people may vanish when the trial is repeated in 200.
How to read around it
Treat this as a signal, not proof. Look for larger replications before changing your behavior based on the result.
Short duration
What it means
The trial ran for weeks when the outcome it claims to affect usually takes months or years to change.
Why it matters
Short trials catch early biomarker shifts but miss tolerance, plateaus, side effects that appear later, and whether the benefit sustains.
How to read around it
Useful for acute effects (sleep, mood, energy). Weak evidence for chronic claims (bone density, cardiovascular risk, aging).
Single-center
What it means
All participants were recruited and treated at one clinic or institution.
Why it matters
Single-center trials reflect one practice pattern, one population, and one set of local confounders. Effects often shrink in multi-center replications.
How to read around it
Consistent with a real effect, but the magnitude is probably optimistic. Multi-center replications give better generalizability.
No active comparator
What it means
The study compared the supplement to a placebo rather than to an established treatment.
Why it matters
Beating placebo only tells you the supplement has some effect. It doesn't tell you whether it's better, worse, or equivalent to existing options.
How to read around it
Fine for novel claims. Weak evidence for 'X works as well as Y' style claims unless Y was actually in the trial.
Unreplicated
What it means
No independent research group has repeated this finding in a separate population.
Why it matters
Roughly half of nutrition and biomedical findings don't replicate. A single positive trial — even a well-run one — is a hypothesis, not a fact.
How to read around it
Wait for replication before investing in a supplement based on a single unreplicated trial.
About the supplement
Boswellia (Frankincense)
Dose · mechanism · evidence grade · safety →
Read the full paper
How to read a study like this
The same questions worth asking about any research paper, not just this one. Worth a minute even if you trust the grade.
Who was studied, and do you resemble them?
Supplement effects often depend on baseline status. Vitamin D helps people who are deficient; iron helps people who are anemic. A result in people unlike you may not apply to you.
What was measured, and does it matter in daily life?
A study that shows a blood marker moved isn't the same as a study that shows people felt or functioned better. Ask what the outcome means in practice.
How large was the effect — not just whether it was significant.
'Statistically significant' only means the effect is unlikely to be zero. It doesn't tell you the effect is large enough to notice. Look for effect sizes, not just p-values.
Who paid for the trial, and what did they stand to gain?
Industry-funded trials are several times more likely to report positive results than independent ones. It's not usually fraud — it's subtle design and reporting choices. Weight accordingly.
Has anyone else replicated this?
Single positive trials are hypotheses. Replication by independent groups is what turns a hypothesis into reliable evidence. If the only positive trial is the one you're reading, wait.
Does the dose in the trial match what's being sold?
Supplement marketing routinely cites trials that used 5–10× the dose in the product. If the effective dose was 2 g/day and the capsule has 200 mg, expect roughly no effect.
About this page
Formulate maintains a registry of clinical studies cited across its guides and evidence grades. This page links the study metadata to the content that cites it — one canonical entry per landmark study.
The full citation chain is public so readers can verify claims without hunting through individual guide pages. Browse all cited studies →
Note: Study summaries on this page are editorial interpretations of the research. Always consult the primary source before drawing clinical conclusions.